This study, called ProGRESS, is looking at new ways to screen for prostate cancer, which is common among Veterans. Current screening methods can be inaccurate, sometimes leading to unnecessary biopsies. This study compares two approaches: a "precision screening intervention" where you receive a report about your genetic risk for prostate cancer, along with personalized screening advice and genetic counseling if your risk is high. The other approach is "usual care," which involves a brochure about making decisions for prostate cancer screening. The goal is to see if genetic testing can better identify men at high risk for serious prostate cancer, while helping those at low risk avoid unneeded biopsies. You may be able to join if you are a male Veteran, aged 55-69, receive regular VA care, and have no personal history of prostate cancer or prior prostate procedures. The study aims to enroll 5000 participants.

Study design

This is an interventional study comparing two different approaches to prostate cancer screening. It plans to enroll 5000 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will follow participants for 7 years to measure the diagnosis of clinically significant prostate cancer and negative prostate biopsies.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.